Berkeley Capital Partners LLC Has $2.27 Million Stock Position in Bristol Myers Squibb Company $BMY

Berkeley Capital Partners LLC lifted its stake in Bristol Myers Squibb Company (NYSE:BMY) by 9.6% during the 2nd quarter, HoldingsChannel reports. The fund owned 49,072 shares of the biopharmaceutical company’s stock after buying an additional 4,305 shares during the period. Bristol Myers Squibb comprises approximately 0.6% of Berkeley Capital Partners LLC’s portfolio, making the stock its 29th biggest holding. Berkeley Capital Partners LLC’s holdings in Bristol Myers Squibb were worth $2,272,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the business. Beacon Investment Advisory Services Inc. boosted its stake in Bristol Myers Squibb by 2.7% during the first quarter. Beacon Investment Advisory Services Inc. now owns 8,063 shares of the biopharmaceutical company’s stock worth $492,000 after buying an additional 212 shares in the last quarter. Exchange Capital Management Inc. boosted its stake in Bristol Myers Squibb by 0.4% during the second quarter. Exchange Capital Management Inc. now owns 54,893 shares of the biopharmaceutical company’s stock worth $2,541,000 after buying an additional 220 shares in the last quarter. Parsons Capital Management Inc. RI boosted its stake in Bristol Myers Squibb by 0.3% during the second quarter. Parsons Capital Management Inc. RI now owns 78,105 shares of the biopharmaceutical company’s stock worth $3,615,000 after buying an additional 224 shares in the last quarter. Richwood Investment Advisors LLC boosted its stake in Bristol Myers Squibb by 1.7% during the second quarter. Richwood Investment Advisors LLC now owns 13,303 shares of the biopharmaceutical company’s stock worth $616,000 after buying an additional 225 shares in the last quarter. Finally, Lipe & Dalton boosted its stake in Bristol Myers Squibb by 0.4% during the first quarter. Lipe & Dalton now owns 56,999 shares of the biopharmaceutical company’s stock worth $3,476,000 after buying an additional 230 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Wall Street Analyst Weigh In

BMY has been the topic of a number of recent research reports. Citigroup reiterated a “neutral” rating on shares of Bristol Myers Squibb in a research note on Monday, October 13th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Bristol Myers Squibb in a research note on Tuesday, October 14th. Dbs Bank upgraded shares of Bristol Myers Squibb to a “moderate buy” rating in a research note on Thursday, October 2nd. Daiwa Capital Markets downgraded shares of Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 target price on the stock. in a research note on Tuesday, August 5th. Finally, Morgan Stanley restated a “hold” rating on shares of Bristol Myers Squibb in a research note on Thursday, July 31st. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and fourteen have issued a Hold rating to the stock. According to data from MarketBeat, Bristol Myers Squibb currently has an average rating of “Hold” and a consensus price target of $57.23.

Insider Activity

In related news, EVP David V. Elkins sold 56,000 shares of Bristol Myers Squibb stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total value of $2,650,480.00. Following the completion of the transaction, the executive vice president directly owned 167,379 shares of the company’s stock, valued at $7,922,048.07. The trade was a 25.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 0.09% of the stock is owned by corporate insiders.

Bristol Myers Squibb Stock Performance

Bristol Myers Squibb stock opened at $43.61 on Tuesday. The stock has a 50-day simple moving average of $46.03 and a 200 day simple moving average of $47.32. The company has a quick ratio of 1.11, a current ratio of 1.21 and a debt-to-equity ratio of 2.54. Bristol Myers Squibb Company has a 12-month low of $42.96 and a 12-month high of $63.33. The stock has a market capitalization of $88.76 billion, a price-to-earnings ratio of 17.58, a P/E/G ratio of 2.27 and a beta of 0.33.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.07 by $0.39. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The business had revenue of $12.27 billion during the quarter, compared to analysts’ expectations of $11.32 billion. During the same period in the previous year, the business posted $2.07 earnings per share. The firm’s revenue for the quarter was up .6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. On average, research analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 3rd. Investors of record on Friday, October 3rd will be issued a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.7%. The ex-dividend date of this dividend is Friday, October 3rd. Bristol Myers Squibb’s payout ratio is currently 100.00%.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.